➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,566,331

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,566,331
Title:Vaccine immunotherapy
Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-.alpha., and IFN-.gamma., and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
Inventor(s): Hadden; John W. (Cold Spring Harbor, NY), Signorelli; Kathy L. (Kings Park, NY), Egan; James E. (Stony Brook, NY), Naylor; Paul H. (Lindenhurst, NY)
Assignee: IRX Therapeutics, Inc. (New York, NY)
Application Number:13/771,622
Patent Claims:see list of patent claims

Details for Patent 9,566,331

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb NULOJIX belatacept INJECTABLE; INJECTION 125288 001 2011-06-15   Start Trial IRX Therapeutics, Inc. (New York, NY) 2029-05-15 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23   Start Trial IRX Therapeutics, Inc. (New York, NY) 2029-05-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.